PLIANT THERAPEUTICS Reports 95.0% Decrease in Revenue for FY2023 Q2

August 17, 2023

🌥️Earnings Overview

On August 9 2023, PLIANT THERAPEUTICS ($NASDAQ:PLRX) released their FY2023 Q2 earnings (ending June 30 2023), showing a 95.0% year-over-year decline in total revenue to USD 0.2 million. Net income was reported at USD -41.2 million, compared to -29.6 million in FY2022 Q2.


GoodWhale has performed an analysis of PLIANT THERAPEUTICS‘s fundamentals and classified them according to Star Chart as an ‘elephant’ – a type of company that is rich in assets after deducting off liabilities. This makes PLIANT THERAPEUTICS an attractive company for a variety of investors. Its intermediate health score of 4/10, considering its cashflows and debt, suggests that it is likely to sustain future operations in times of crisis. Furthermore, PLIANT THERAPEUTICS is strong in asset, medium in growth, profitability and weak in dividend, making it a company that is strong in capital and medium in other areas. This can be attractive to investors who are looking for a stable capital base as well as moderate growth potential. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Pliant Therapeutics. More…

    Total Revenues Net Income Net Margin
    5.03 -144.41 -2872.8%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Pliant Therapeutics. More…

    Operations Investing Financing
    -104.77 -355.42 490.07
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Pliant Therapeutics. More…

    Total Assets Total Liabilities Book Value Per Share
    574.89 41.83 9.01
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Pliant Therapeutics are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -61.7% -2848.0%
    FCF Margin ROE ROA
    -2116.6% -16.3% -15.6%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items

  • Peers

    In the biopharmaceutical industry, Pliant Therapeutics Inc is up against some tough competition from the likes of Epizyme Inc, Kinnate Biopharma Inc, and PhaseBio Pharmaceuticals Inc. All of these companies are striving to develop innovative new therapies to treat a variety of diseases. Pliant Therapeutics Inc is focused on developing treatments for fibrotic diseases, while its competitors are working on therapies for cancer, genetic disorders, and other diseases. While all of these companies are working towards similar goals, they are all also vying for a limited pool of resources. This competition is likely to continue in the future as all of these companies attempt to bring their groundbreaking therapies to market.

    – Epizyme Inc ($NASDAQ:KNTE)

    Kinnate Biopharma Inc is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics for the treatment of cancer. The company’s product candidate, KIN001, is a first-in-class inhibitor of the tyrosine kinase activity of the c-Met receptor, which is overexpressed in various solid tumors. Kinnate Biopharma Inc has a market cap of 384.51M as of 2022 and a Return on Equity of -27.29%. The company’s focus on developing novel small molecule therapeutics makes it an attractive option for investors looking to gain exposure to the growing biopharmaceutical industry.

    – Kinnate Biopharma Inc ($NASDAQ:PHAS)

    In 2022, Alnylam Pharmaceuticals had a market cap of $5.33 million and a return on equity of 58.1%. The company focuses on the development and commercialization of RNAi therapeutics for the treatment of genetically defined diseases.


    PLIANT THERAPEUTICS reported concerning financial results for FY2023 Q2, with total revenue of USD 0.2 million and a net loss of USD 41.2 million. Investors should consider this information carefully when analyzing the potential of investing in PLIANT THERAPEUTICS, given the uncertain future outlook for the company. Despite some positive signs, such as PLIANT THERAPEUTICS’ strategic partnerships and the potential for new products in the pipeline, these financial metrics will need to improve before confidence in the stock can be restored.

    Recent Posts

    Leave a Comment